Nuvation Bio Inc.
NUVB- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001811063
In the last 90 days, Nuvation Bio Inc. insiders filed 0 open-market purchases and 1 sale; 271 institutions reported holding it in 13F filings for Q2 2026, worth $1.60B in total; 3 superinvestors hold it, including Duquesne Family Office and Abrams Capital.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $709.2K in total
- 1
- 13F holdersQ2 2026, +41 vs. previous quarter
- 271
- 13F valueReported value at the end of Q2 2026
- $1.60B
- Superinvestors holdingAt the end of Q2 2026
- 3
Price chart
Superinvestors holding NUVB, Q2 2026
3 superinvestors report holding Nuvation Bio Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Duquesne Family Office
Stanley Druckenmiller
0.6%
Nuvation Bio Inc.'s share of the portfolio
- Shares
- 4,539,800
- Value
- $25.8M
| Superinvestor | Weight | Value |
|---|---|---|
| Greenlight Capital | <0.1% | $198.8K |
Latest insider trades
Open-market purchases and sales by Nuvation Bio Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 21, 2026 (view filing)4:49 PM ET | Aug 19 | 2 days | Hattersley GaryCHIEF SCIENTIFIC OFFICER | SSaleClass A Common Stock | −100.0K | $7.09 | −$709.2K | −100.0%0 after | 10b5-1 |
| Jun 24, 2026 (view filing) | Jun 23 | 1 day | Sauvage PhilippeChief Financial Officer | SSaleClass A Common Stock | −47.7K | $6.01 | −$286.5K | −79.0%12.7K after | 10b5-1 |
| Jun 24, 2026 (view filing) | Jun 23 | 1 day | Markel StacyCHIEF PEOPLE OFFICER | SSaleClass A Common Stock | −125.0K | $6.03 | −$753.8K | −79.3%32.6K after | 10b5-1 |
| Jun 24, 2026 (view filing) | Jun 23 | 1 day | Wentworth KerryCHIEF REGULATORY OFFICER | SSaleClass A Common Stock | −63.0K | $6.02 | −$379.3K | −54.3%53.0K after | 10b5-1 |
| Jun 11, 2026 (view filing) | Jun 9 | 2 days | Mashal RobertDirector | PPurchaseClass A Common Stock | +25.0K | $4.73 | +$118.3K | +12.5%225.0K after | |
| Apr 21, 2026 (view filing) | Apr 17 | 4 days | Liu DongfangCHIEF MEDICAL OFFICER | SSaleClass A Common Stock | −50.0K | $5.02 | −$251.0K | −73.5%18.0K after | 10b5-1 |
| Apr 21, 2026 (view filing) | Apr 17 | 4 days | Wentworth KerryCHIEF REGULATORY OFFICER | SSaleClass A Common Stock | −36.8K | $5.01 | −$184.1K | −40.9%53.0K after | 10b5-1 |
| Apr 8, 2026 (view filing) | Apr 6 | 2 days | Wentworth KerryCHIEF REGULATORY OFFICER | SSaleClass A Common Stock | −200.0K | $4.52 | −$904.0K | −79.1%53.0K after | 10b5-1 |
| Dec 3, 2025 (view filing) | Dec 1 | 2 days | Liu DongfangCHIEF MEDICAL OFFICER | SSaleClass A Common Stock | −150.0K | $7.82 | −$1.17M | −89.3%18.0K after | |
| Nov 26, 2025 (view filing) | Nov 25-26 | 1 day | Liu DongfangCHIEF MEDICAL OFFICER | SSaleClass A Common Stock | −20.0K | $7.75 | −$155.0K | −52.6%18.0K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Nuvation Bio Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 52,230,295 | $296.7M | 0.01% | +240,702+0.5% | Added |
| BlackRock, Inc. | 27,630,837 | $162.3M | 0.00% | +2,530,463+10.1% | Added |
| Decheng Capital LLC | 25,954,439 | $147.4M | 20.15% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 11,919,514 | $67.7M | 0.00% | +293,316+2.5% | Added |
| Linden Advisors LP | – | $54.9M | 0.28% | – | New |
| Omega Fund Management, LLC | 8,081,089 | $45.9M | 24.72% | 00.0% | Unchanged |
| Laurion Capital Management LP | 7,820,013 | $44.4M | 3.22% | −2,6250.0% | Reduced |
| State Street Corp | 7,370,794 | $41.9M | 0.00% | +585,867+8.6% | Added |
| Geode Capital Management, LLC | 6,244,805 | $35.5M | 0.00% | +381,151+6.5% | Added |
| D. E. Shaw & Co., Inc. | 1,140,000 | $35.2M | 0.02% | +747,014+190.1% | Added |